Taner ALIÇ, ALPER ÇIRAKLI, Yılmaz ŞAHİN, Yılmaz TOMAK

Effects of cilostazol on fracture healing: an experimental study

Objective: The aim of this experimental study was to examine the clinical, radiological and histological effects of cilostazol on fracture healing.Methods: A total of 60 Wistar albino male rats were divided into 2 groups: the study group (cilostazol) and the control group. Under general anesthesia, using a blunt-ended guillotine, standard closed shaft fractures were formed on the 3-point principle in the left femurs. Starting on the same day after the fracture was formed until sacrifice, the study group animals were administered with cilostazol (50 mg/kg/day, oral tablet). An equal number of rats from both control and study groups were sacrificed on the 7th, 14th, and 21st days after fracture formation, and the bone union tissue was examined clinically, radiologically and histologically. Results: The use of cilostazol was not determined to have any significant effect clinically or radiologically on fracture healing (p>0.05). According to the histological findings, at the end of the first week, the amount of union in the cilostazol group was observed to be significantly greater (p<0.05). At the end of the third week, no significant difference was determined between the control and study groups (p>0.05).Conclusion: In the long term, cilostazol did not show any positive effect on fracture healing clinically, radiologically or histologically.

___

Ozaki A, Tsunoda M, Kinoshita S, Saura R. Role of frac- ture hematoma and periosteum during fracture healing in rats: interaction of fracture hematoma and the perios- teum in the initial step of the healing process. J Orthop Sci 2000;5:64-70.

O'Donnell ME, Badger SA, Sharif MA, Makar RR, McEneny J, Young IS, et al. The effects of cilostazol on exercise-induced ischaemia-reperfusion injury in patients with peripheral arterial disease. Eur J Vasc Endovasc Surg 2009;37:326-35.

Bonnarens F, Einhorn TA. Production of a standard closed fracture in laboratory animal bone. J Orthop Res 1984;2:97-101.

Dimar JR 2nd, Ante WA, Zhang YP, Glassman SD. The effects of nonsteroidal anti-inflammatory drugs on pos- terior spinal fusions in the rat. Spine (Phila Pa 1976) 1996;21:1870-6.

Lane JM, Sandhu HS. Current approaches to experimental bone grafting. Orthop Clin North Am 1987;12:213-25.

Huo MH, Troiano NW, Pelker RR, Gundberg CM, Fried- laender GE. The influence of ibuprofen on fracture repair: biomechanical, biochemical, histologic, and histomorpho- metric parameters in rats. J Orthop Res 1991;9:383-90.

Sevimli R, Uzel M, Sayar H, Kalender AM, Dökmeci O. The effect of dexketoprofen trometamol on the healing of diaphysis fractures of rat tibia. Acta Orthop Traumatol Turc 2013;47:423-9.

Costa ER, Weinhold P, Tayrose GA, Hooker JA, Dahners LE. The effect of levodopa or levodopa-carbidopa (sinemet) on fracture healing. J Orthop Trauma 2006;20:470-5.

Saraf SK, Singh A, Garbyal RS, Singh V. Effect of simvas- tatin on fracture healing--an experimental study. Indian J Exp Biol 2007;45:444-9.

Adah F, Benghuzzi H, Tucci M, Russell G, England B. Cholesterol production inhibitor (statin) increased bone healing in surgically created femoral defect in an animal model. Biomed Sci Instrum 2007;43:95-103.

Serin-Kilicoglu S, Erdemli E. New addition to the statin's effect. J Trauma 2007;63:187-91.

Polat O, Kilicoglu SS, Erdemli E. A controlled trial of glu- tamine effects on bone healing. Adv Ther 2007;24:154- 60.

Baldik Y, Talu U, Altinel L, Bilge H, Demiryont M, Aykac-Toker G. Bone healing regulated by nitric oxide: an experimental study in rats. Clin Orthop Relat Res 2002;404:343-52.

Perry AC, Prpa B, Rouse MS, Piper KE, Hanssen AD, Steckelberg JM, et al. Levofloxacin and trovafloxacin inhi- bition of experimental fracture-healing. Clin Orthop Relat Res 2003;414:95-100.

Ince A, Schütze N, Karl N, Löhr JF, Eulert J. Gentamicin negatively influenced osteogenic function in vitro. Int Or- thop 2007;31:223-8.

Erdem M, Gülabi D, Aşçı M, Bostan B, Güneş T, Köseoğlu RD. The effects of melatonin and caffeic acid phenethyl es- ter (CAPE) on fracture healing under ischemic conditions. Acta Orthop Traumatol Turc 2014;48:339-45.

Halıcı M, Öner M, Güney A, Canöz Ö, Narin F, Halıcı C. Melatonin promotes fracture healing in the rat model. Eklem Hastalik Cerrahisi 2010;21:172-7.

Kerimoğlu G, Yuluğ E, Kerimoğlu S, Çıtlak A. Effects of leptin on fracture healing in rat tibia. Eklem Hastalik Cer- rahisi 2013;24:102-7.

Aydin K, Sahin V, Gürsu S, Mercan AS, Demir B, Yildirim T. Effect of pentoxifylline on fracture healing: an experi- mental study. Eklem Hastalik Cerrahisi 2011;22:160-5.

Akkaya S, Nazalı M, Kılıç A, Bir F. Cefazolin-sodium has no adverse effect on fracture healing in an experimental rabbit model. Eklem Hastalik Cerrahisi 2012;23:44-8.

Koçer A, Öner M, Karaman İ, Koçer D, Kafadar İH, Güney A, et al. The effects of locally applied simvastatin on an experimental mouse femur nonunion model. Acta Orthop Traumatol Turc 2014;48:679-84.

Chapman TM, Goa KL. Cilostazol: a review of its use in intermittent claudication. Am J Cardiovasc Drugs 2003;3:117-38.

Westerhuis RJ, van Bezooijen RL, Kloen P. Use of bone morphogenetic proteins in traumatology. Injury 2005;36:1405-12.

Eckardt H, Christensen KS, Lind M, Hansen ES, Hall DW, Hvid I. Recombinant human bone morphogenetic protein 2 enhances bone healing in an experimental model of fractures at risk of non-union. Injury 2005;36:489-94.

Horiuchi H, Saito N, Kinoshita T, Wakabayashi S, Tsu- tsumimoto T, Otsuru S, et al. Enhancement of recombi- nant human bone morphogenetic protein-2 (rhBMP-2)- induced new bone formation by concurrent treatment with parathyroid hormone and a phosphodiesterase inhibitor, pentoxifylline. J Bone Miner Metab 2004;22:329-34.

Kinoshita T, Kobayashi S, Ebara S, Yoshimura Y, Horiu- chi H, Tsutsumimoto T, et al. Phosphodiesterase in- hibitors, pentoxifylline and rolipram, increase bone mass mainly by promoting bone formation in normal mice. Bone 2000;27:811-7.

Wakabayashi S, Tsutsumimoto T, Kawasaki S, Kinoshita T, Horiuchi H, Takaoka K. Involvement of phosphodies- terase isozymes in osteoblastic differentiation. J Bone Min- er Res 2002;17:249-56.

Yamagami H, Nishioka T, Ochiai E, Fukushima K, No- mura M, Kasugai S, et al. Inhibition of osteoclastogenesis by a phosphodiesterase 4 inhibitor XT-611 through syner- gistic action with endogenous prostaglandin E2. Biochem Pharmacol 2003;66:801-7.

Waki Y, Horita T, Miyamoto K, Ohya K, Kasugai S. Ef- fects of XT-44, a phosphodiesterase 4 inhibitor, in osteo- blastgenesis and osteoclastgenesis in culture and its thera- peutic effects in rat osteopenia models. Jpn J Pharmacol 1999;79:477-83.

Takami M, Cho ES, Lee SY, Kamijo R, Yim M. Phospho- diesterase inhibitors stimulate osteoclast formation via TRANCE/RANKL expression in osteoblasts: possible involvement of ERK and p38 MAPK pathways. FEBS Lett 2005;579:832-8.

Omi H, Okayama N, Shimizu M, Fukutomi T, Nakamura A, Imaeda K, et al. Cilostazol inhibits high glucose-medi- ated endothelial-neutrophil adhesion by decreasing adhe- sion molecule expression via NO production. Microvasc Res 2004;68:119-25.

Kim MJ, Lee JH, Park SY, Hong KW, Kim CD, Kim KY, et al. Protection from apoptotic cell death by cilostazol, phosphodiesterase type III inhibitor, via cAMP-dependent protein kinase activation. Pharmacol Res 2006;54:261-7.

Simpson AH, Mills L, Noble B. The role of growth factors and related agents in accelerating fracture healing. J Bone Joint Surg Br 2006;88:701-5.

Schmidmaier G, Wildemann B, Heeger J, Gäbelein T, Fly- vbjerg A, Bail HJ, et al. Improvement of fracture healing by systemic administration of growth hormone and local ap- plication of insulin-like growth factor-1 and transforming growth factor-beta1. Bone 2002;31:165-72.